Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Don't Show The Whole Picture
Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Don't Show The Whole Picture
Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed strength. We think that investors might be looking at some positive factors beyond the earnings numbers.
Vcanbio Cell & Gene Engineering Corp., Ltd(上海证券交易所股票代码:600645)最近的疲软利润数字似乎并没有让股东感到担忧,因为股价表现出强劲。我们认为,除了收益数字外,投资者可能会考虑一些积极因素。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240906/0-7ad923deee304acca1a899fc8315a3fd-0-0dd36e06178db524a73a37bc48901efb.png/big)
The Impact Of Unusual Items On Profit
不寻常物品对利润的影响
Importantly, our data indicates that Vcanbio Cell & Gene Engineering's profit was reduced by CN¥23m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If Vcanbio Cell & Gene Engineering doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.
重要的是,我们的数据表明,由于异常项目,Vcanbio细胞与基因工程的利润比去年减少了2300万元人民币。看到不寻常的项目使公司利润损失从来都不是一件好事,但从好的方面来看,情况可能迟早会好转。我们调查了数千家上市公司,发现不寻常的物品本质上往往是一次性的。而且,毕竟,这正是会计术语的含义。如果Vcanbio细胞与基因工程没有看到这些不寻常的支出重演,那么在其他条件相同的情况下,我们预计其利润将在来年增加。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。
Our Take On Vcanbio Cell & Gene Engineering's Profit Performance
我们对Vcanbio细胞与基因工程盈利表现的看法
Because unusual items detracted from Vcanbio Cell & Gene Engineering's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that Vcanbio Cell & Gene Engineering's statutory profit actually understates its earnings potential! Unfortunately, though, its earnings per share actually fell back over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Obviously, we love to consider the historical data to inform our opinion of a company. But it can be really valuable to consider what other analysts are forecasting. So feel free to check out our free graph representing analyst forecasts.
由于不寻常的项目削弱了Vcanbio Cell & Geneineering去年的收益,你可能会争辩说,我们可以预期本季度的业绩会有所改善。基于这一观察,我们认为Vcanbio Cell & Gene Engineering的法定利润实际上可能低估了其盈利潜力!但不幸的是,其每股收益实际上在去年有所回落。本文的目标是评估我们在多大程度上可以依靠法定收益来反映公司的潜力,但还有很多需要考虑的地方。显然,我们喜欢考虑历史数据来为我们对公司的看法提供依据。但是,考虑其他分析师的预测可能非常有价值。因此,请随时查看我们代表分析师预测的免费图表。
Today we've zoomed in on a single data point to better understand the nature of Vcanbio Cell & Gene Engineering's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天,我们放大了单一数据点,以更好地了解Vcanbio细胞与基因工程利润的性质。但是,如果你能够将注意力集中在细节上,总会有更多的事情需要发现。有些人认为高股本回报率是优质业务的好兆头。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份拥有大量内幕持股的股票清单很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。